GeneDx Holdings Corp.

Estimates and assumptions utilized in the Monte Carlo simulation model include risk-adjusted forecasted revenue and gross margin, revenue and gross profit volatility rates, expected stock price volatility, and discount rates which are based on the cost of debt and equity.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

Long-Term Debt As of June 30, 2026, long-term debt matures as follows: Term loan due 2031 $ 100,000 Less: debt issuance costs ( 3,164 ) Total long-term debt, net of debt issuance costs $ 96,836 Blackstone Loan Agreement On February 27, 2026 (the Signing Date ), the Company entered into a Loan Agreement (the Loan Agreement ), among Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

The Loan Agreement provides for a term loan in an aggregate principal amount of $ 100.0 million (the Term Loan ), which was funded to the Company on February 27, 2026 (the Closing Date ).

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

The Term Loan bears interest at a rate equal to the Term SOFR adjusted secured overnight financing rate plus a margin of 4.50 %.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

The Term Loan includes a SOFR floor of 1.50 %.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

If an event of default occurs and is continuing, all amounts outstanding under the Loan Agreement will bear additional interest at a per annum rate equal to 2.00 % plus the rate otherwise applicable to the Term Loan.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

These forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate, intend, strategy, future, opportunity, plan, may, should, will, would, will be, will continue, will likely result, and similar expressions.

SEC original ↗GeneDx Holdings Corp. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform.

SEC original ↗GeneDx Holdings Corp. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform.

SEC original ↗GeneDx Holdings Corp. — Presentation / slide deck (8-K exhibit)EX-99Jul 29, 2025

Goodwill and Intangible Assets The change in the carrying amount of goodwill during the six months ended June 30, 2026 was as follows: Balance at December 31, 2025 $ 13,520 Impairment charges ( 11,879 ) Balance at June 30, 2026 $ 1,641 During the first quarter of 2026, the Company concluded that a triggering event had occurred during the period for the goodwill associated with the Fabric Genomics reporting unit primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

The Company s obligations under the Amended Loan Agreement are guaranteed by certain of its subsidiaries and secured by a first-priority lien on substantially all of the assets of the Company and the Guarantors.

SEC original ↗GeneDx Holdings Corp. — 10-Q Quarterly report10-QAug 3, 2026

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

SEC original ↗GeneDx Holdings Corp. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

You should carefully consider the foregoing factors and the other risks and uncertainties described in the Risk Factors sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.

SEC original ↗GeneDx Holdings Corp. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

SEC original ↗GeneDx Holdings Corp. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

We discuss these and other risks and uncertainties in greater detail in the sections entitled Risk Factors and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports and other filings we make with the SEC from time to time.

SEC original ↗GeneDx Holdings Corp. — Presentation / slide deck (8-K exhibit)EX-99Jul 29, 2025

Given these uncertainties, you should not place undue reliance on the forward-looking statements.

SEC original ↗GeneDx Holdings Corp. — Presentation / slide deck (8-K exhibit)EX-99Jul 29, 2025

For the three months ended June 30, 2024, represents interest expense, net, income tax benefit, net, and reserves net of insurance for a certain litigation matter.

SEC original ↗GeneDx Holdings Corp. — Presentation / slide deck (8-K exhibit)EX-99Jul 29, 2025